NTLA250117C2500
- 0.00
- 0.000.00%
Intellia Therapeutics Newsroom
Peering Into Intellia Therapeutics's Recent Short Interest
Cathie Wood's ARK Investment Buys 96.2K Shares of Intellia Therapeutics Today
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Express News | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost
Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis With Polyneuropathy
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Cathie Wood's ARK Investment Buys 223.5K Shares of Intellia Therapeutics Today
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90